InvestorsHub Logo

Here Today

05/02/21 1:38 PM

#357746 RE: biopa #357742

He’s “reaching” even on a Sunday. To think he accuses others of not knowing anything about trials and all he does is copy and pastes off of google.... When a trial is scheduled, normally you would have produced an amount far greater than what the study calls for since there is a vast amount of sites administering the drug. So you would need each site with a certain quantity since the clinical trial sites would already have the drug on hand to administer so that when a candidate states they wish to participate, they can already be given either the drug or placebo. So with already 11 Clinical Sites, it would be safe to say that IPIX had produced up over 500 doses since each site would require and receive a certain quantity. Also there is the Compassionate Use and Right to Try laws which IPIX would need supply on hand for when needed. That’s my assessment.

sunspotter

05/02/21 2:59 PM

#357754 RE: biopa #357742

“Why do you say B is difficult and costly to produce?”

I didn’t. I said randomised, labelled, blinded clinical trial supplies of active and placebo are difficult and expensive to produce.

Anyone who had been involved in clinical studies should know that.